Servier UK
Kelly Gomes has a wide range of experience in the pharmaceutical industry, primarily with Servier. Starting in 2005, they worked as an NHS Projects Coordinator before becoming a Key Account Manager in the Cardiovascular/Osteoporosis division in 2009. In 2014, they transitioned to a role as a Healthcare Development Manager, focused on creating strategic plans and value-based partnership solutions for heart failure patients. In 2015, they received the "Top Contributor" STAR award for field medical affairs. From 2015 to 2018, Kelly worked as a Medical Science Liaison in the newly formed Oncology division, establishing Servier's reputation in oncology and building relationships with key opinion leaders. Kelly then transitioned to the role of Medical Science Liaison/Scientific Trainer, where they were responsible for NICE submissions and scientific training. Most recently, Kelly has been serving as the Medical Lead - Oncology at Servier UK, providing medical scientific expertise and leading strategy development in oncology disciplines. Kelly also contributes to market access and medical strategy at a UK and global level.
Kelly Gomes completed their Bachelor of Science degree in Biology at Aston University. Following that, they pursued a Wellcome Trust PhD in Biochemistry of Cellular Systems at the University of Manchester, focusing on the study of BASP1 as a co-repressor of the Wilms tumour suppressor (WT1).
This person is not in any teams
This person is not in any offices
Servier UK
1 followers
Servier is an international pharmaceutical company governed by a non-profit foundation with its headquarters in Suresnes (France). With a strong international presence in 149 countries and a turnover of 4.615 billion euros in 2019, Servier employs 22,000 people worldwide. Corporate growth is driven by Servier's constant search for innovation in five areas of excellence: cardiovascular diseases, diabetes, cancers, immune-inflammatory diseases, and neurodegenerative diseases, as well as by its activities in high-quality generic drugs. Being completely independent, the Group reinvests 25% of turnover (excluding generics) in research and development and uses all its profits for growth. Servier was created in 1954, and in 1964 Servier UK was the first subsidiary to open, with just two employees. To report a side effect with one of our products, please visit https://www.servier.co.uk/report-a-side-effect/ Reporting forms and information can also be found at www.mhra.gov.uk/yellowcard